Navigation Links
12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis
Date:8/19/2008

SYDNEY, Australia, Aug. 20 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the Phase 3 clinical trial evaluating the long term safety of Bronchitol in subjects with bronchiectasis has concluded with no serious adverse events attributed to the drug following 12 months of treatment.

A total of 123 subjects started treatment with 320 mg Bronchitol twice per day and 99 subjects completed the full 12 months of the trial. Of the 24 withdrawals, only seven were a result of adverse events (three related to lung infections and two related to cough).

The most common adverse events attributed to treatment were cough in 9% of the subjects and sore throat in 5%. Other reported adverse events related to treatment were infrequent, mild in severity and in most cases were a consequence of the underlying disease.

Pharmaxis CEO Alan Robertson said: "Pharmaxis intends to file a marketing application in Australia for Bronchitol as soon as possible now that this study has concluded satisfactorily.

"Bronchitol has created a great deal of interest among people suffering with bronchiectasis and we continue to respond to requests from trial participants and others interested in Bronchitol. We are looking forward to bringing Bronchitol to the market place and are delighted this trial has concluded successfully."

This 12 month treatment period was an open label extension to a three month efficacy trial which reported in the second half of 2007.

The conclusion from this trial is that Bronchitol improves quality of life and mucus clearance following three months of treatment and is safe and well tolerated following 12 months of treatment. The open label component of the trial reported today supports the efficacy reported earlier in the blinded phase of the trial.

Bronchitol is being initially developed as a twice daily inhalation therapy for people with the incurable lung condi
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
2. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
3. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
4. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
5. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
6. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
7. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
8. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
9. Clinical Update - Decapeptyl(R)/Trelstar(R) 6-Month Formulation in Advanced Prostate Cancer
10. Phase III Data Published for Once Monthly Dose of Risedronate to Treat Postmenopausal Osteoporosis
11. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 The breakthrough hepatitis C treatment, Sovaldi ... manufacturer Gilead Sciences overcame initial market resistance through its ... relations campaigns. Sovaldi,s high cure rate, short ... propelled the drug to $2.3 billion in sales during ... on the market. But Sovaldi,s price tag of $84,000 ...
(Date:5/1/2015)... 01, 2015 /PRNewswire/ --Research and Markets ( ... Clinical Chemistry Analyzer Market by Product, by End-Users - Forecast ... American Clinical Chemistry Analyzers market is estimated to grow at ... as the U.S., Canada , ... of Americas (RoA) are covered in this report. ...
(Date:5/1/2015)... LITTLE FALLS, N.J. , May 1, 2015 ... Andrew A. Krakauer , Chief Executive Officer, will be ... Conference at the Encore at the Wynn in ... for Thursday, May 14, 2015 at 10:00 AM PT/1:00 PM ... meetings during the day. An audio webcast ...
Breaking Medicine Technology:New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2Americas Clinical Chemistry Analyzer (Semi-Automated Clinical Chemistry and Fully-Automated Clinical Chemistry) Market - Forecast to 2019 2
... QUAD Cinema , one of New York City,s leading art ... documentary, 3 BILLION AND COUNTING (102 ... Sure to spark outrage, Dr. Rutledge, a California physician ... ban on the pesticide DDT in 1972, a ban inspired ...
... The following is a statement issued today ... and CEO Steven C. Anderson, IOM, CAE, and National ... CEO Douglas Hoey, RPh, regarding the proposed rule by ... would withdraw existing provisions of the Medicaid pharmacy reimbursement ...
Cached Medicine Technology:3 BILLION AND COUNTING Opens in New York at The QUAD Cinema 23 BILLION AND COUNTING Opens in New York at The QUAD Cinema 3NACDS, NCPA: Victory for Patients, Pharmacy as CMS Moves to Withdraw Provisions of 'AMP' Rule Currently Blocked by Injunction 2NACDS, NCPA: Victory for Patients, Pharmacy as CMS Moves to Withdraw Provisions of 'AMP' Rule Currently Blocked by Injunction 3
(Date:5/2/2015)... Vancouver fencing company, QS Fencing, has recently announced that its ... related to their questions on railings and gates. Many people ... and patios. While that seems like an easy task, there ... rolls up their sleeve to start working. One of the ... gate that matches it. , Instead of spending hours worrying ...
(Date:5/2/2015)... Delray Beach, FL (PRWEB) May 02, 2015 ... newspaper has selected The Delray Recovery Center as one ... Recovery Center is known in the addiction treatment field ... encourages staff members to innovate and to continue their ... promoting a positive workplace environment, never forgetting their purpose ...
(Date:5/2/2015)... As a nonsurgical staple in ... face, neck and décolleté, radiofrequency energy is proving ... for the success of vulvovaginal rejuvenation. In a ... Council, ThermiGyn’s Women’s Health Clinical Advisory Board Chairman ... ThermiGyn’s temperature controlled radio frequency, specifically that of ...
(Date:5/1/2015)... and Caicos Islands, BWI (PRWEB) May 02, 2015 ... new website! It is http://www.thevenetiangracebay.com , and ... and it incorporates the stunning white and attractive turquoise ... a study of Google, sixty seven percent of leisure ... The study showed that smartphones were used in the ...
(Date:5/1/2015)... Va. (PRWEB) May 01, 2015 The ... nation’s leading nonprofit authority on the use of health ... as a key contributing resource to the United States ... use of electronically readable cards in Medicare. The report, ... and Providers ” was released to the public on ...
Breaking Medicine News(10 mins):Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3
... cancer inevitably involves exposure of normal tissues. Although the ... number of patients experience distressing complications as a result ... inflammatory process cause discomfort and decreases the therapeutic benefit ... research article to be published on December 14, 2008 ...
... highlights of 2008 , , TUESDAY, Dec. 23 (HealthDay ... 2008, as new drugs tackled the toughest cancers with ... prevention and risk factor identification. , A new ... details 12 "major" advances and 19 "notable advances" across ...
... 2 dozen contain dangerous ingredients not listed on label ... Food and Drug Administration warned consumers Monday to avoid ... because they contain undeclared ingredients that could pose serious ... retail stores and on the Internet and some claim ...
... of microscopic particles for molecular imaging, constituting one ... be readily adapted for tumor targeting and treatment ... the investigators at Memorial Sloan-Kettering Cancer Center (MSKCC) ... stable, and small enough to be easily transported ...
... Scientists at the U.S. Department of Energy,s (DOE) ... a third subtype of botulinum neurotoxin a deadly ... botulism, and is also used in cosmetic and therapeutic ... bladder. The detailed structure, published online December 22, 2008, ...
... the perfect job. The not-so-good news it,s contingent ... with diseases like HIV, or those who are simply mega-stressed ... medical exam to qualify for a job can be daunting. ... excellent news. , Medical exams are often not an accurate ...
Cached Medicine News:Health News:What is the mechanism of the chronic radiation enteritis? 2Health News:Cancer Medicine Advances on Many Fronts 2Health News:Cancer Medicine Advances on Many Fronts 3Health News:Cancer Medicine Advances on Many Fronts 4Health News:FDA Warns About Weight Loss Products 2Health News:FDA Warns About Weight Loss Products 3Health News:Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting 2Health News:Researchers create smaller, brighter probe tailored for molecular imaging and tumor targeting 3Health News:Scientists reveal structure of new botulism nerve toxin subtype 2Health News:Scientists reveal structure of new botulism nerve toxin subtype 3Health News:A simple questionnaire to replace a doctor's exam 2
... cardiovascular system PLUS ... high-performance transesophageal cardiovascular imaging system ... phased array echocardiography system that ... images, even on your most ...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
MAGNETOM Avanto, the worlds first Tim MRI system, provides unsurpassed image quality, enhanced productivity, and greater patient comfort....
... Medical Billing Assistant (MBA) ... medical billing and practice management ... on Microsoft SQL Server technology ... reporting capabilities and account receivable ...
Medicine Products: